CN115175912B - N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 - Google Patents

N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 Download PDF

Info

Publication number
CN115175912B
CN115175912B CN202080082800.6A CN202080082800A CN115175912B CN 115175912 B CN115175912 B CN 115175912B CN 202080082800 A CN202080082800 A CN 202080082800A CN 115175912 B CN115175912 B CN 115175912B
Authority
CN
China
Prior art keywords
compound
crystalline form
present disclosure
hormone
xiii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080082800.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115175912A (zh
Inventor
C·雅古施
C·K·赫兹
A·施罗德
P·I·弗拉霍瓦
S·斯蒂威斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Switzerland GmbH
Original Assignee
Sumitomo Pharma Switzerland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Switzerland GmbH filed Critical Sumitomo Pharma Switzerland GmbH
Publication of CN115175912A publication Critical patent/CN115175912A/zh
Application granted granted Critical
Publication of CN115175912B publication Critical patent/CN115175912B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080082800.6A 2019-10-10 2020-10-09 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 Active CN115175912B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913606P 2019-10-10 2019-10-10
US62/913,606 2019-10-10
PCT/EP2020/078475 WO2021069700A1 (en) 2019-10-10 2020-10-09 Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Publications (2)

Publication Number Publication Date
CN115175912A CN115175912A (zh) 2022-10-11
CN115175912B true CN115175912B (zh) 2025-04-11

Family

ID=72852647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080082800.6A Active CN115175912B (zh) 2019-10-10 2020-10-09 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式

Country Status (5)

Country Link
US (1) US20220372044A1 (enExample)
EP (1) EP4041738A1 (enExample)
JP (1) JP7713934B2 (enExample)
CN (1) CN115175912B (enExample)
WO (1) WO2021069700A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3518933T2 (sl) 2016-09-30 2025-05-30 Sumitomo Pharma Switzerland Gmbh Metode zdravljenja materničnih miom in endometrioze
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
JP2023549196A (ja) 2020-11-11 2023-11-22 ミオバント サイエンシズ ゲーエムベーハー レルゴリクスの投与方法
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947734A (zh) * 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101153042A (zh) * 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
TWI508962B (zh) * 2009-04-22 2015-11-21 Du Pont 氮雜環醯胺之固體形態
EP2630146B1 (en) * 2010-10-21 2020-07-01 Medivation Technologies LLC Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
RS58703B1 (sr) * 2012-09-28 2019-06-28 Takeda Pharmaceuticals Co Metoda proizvodnje derivata tienopirimidina
SI3518933T2 (sl) * 2016-09-30 2025-05-30 Sumitomo Pharma Switzerland Gmbh Metode zdravljenja materničnih miom in endometrioze
WO2018060463A2 (en) * 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
US11306104B2 (en) * 2018-03-14 2022-04-19 Teva Pharmaceuticals International Gmbh Solid state forms of Relugolix
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
US20220220123A1 (en) * 2019-05-15 2022-07-14 Dr. Reddy's Laboratories Limited Amorphous and crystalline forms of relugolix
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947734A (zh) * 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法

Also Published As

Publication number Publication date
EP4041738A1 (en) 2022-08-17
US20220372044A1 (en) 2022-11-24
CN115175912A (zh) 2022-10-11
JP7713934B2 (ja) 2025-07-28
JP2022551525A (ja) 2022-12-09
WO2021069700A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
CN115175912B (zh) N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
US11760756B2 (en) Crystalline form of a PD-1/PD-L1 inhibitor
US9844550B2 (en) Phtalazinone derivatives and manufacturing process thereof
EP3227295B1 (en) 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
JP2023508097A (ja) タンパク質分解剤化合物の製造方法及び使用
CN115279769A (zh) N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
TW200521133A (en) Novel 17β-hydroxysteroid dehydrogenase type I inhibitors
US20250171421A1 (en) Enantiomerically purified gper agonist for use in treating disease states and conditions
TW202012384A (zh) 特定芳基普拉二烯內酯化合物及其使用方法
WO2022184103A1 (zh) 三并环化合物及其药物组合物和应用
JP2020536872A (ja) ３−置換１，２，４−オキサジアゾールの結晶形態
CN119744262A (zh) 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途
JP2024546478A (ja) Ｒａｆキナーゼ阻害剤及びその使用方法
TW202444723A (zh) 喜樹鹼衍生物、藥物組合物及其製備方法和用途
CN112979532A (zh) 邻苯二甲酰亚胺类化合物、制备方法和应用
CN114644635B (zh) 三氮唑类三并环衍生物及其制备方法和应用
TW200829572A (en) Crystal modifications
TW202021950A (zh) 作為免疫調節劑的化合物及其製備方法和應用
US20230286900A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
WO2025237404A1 (zh) 一种mc4r拮抗剂的多晶型物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Switzerland

Address after: Basel, SUI

Applicant after: Sumitomo Pharmaceutical Switzerland Ltd.

Address before: Basel, SUI

Applicant before: MYOVANT SCIENCES GmbH

Country or region before: Switzerland

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant